Diamond Equity Forecasts MAIA Biotechnology Q1 Earnings

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) – Equities research analysts at Diamond Equity issued their Q1 2025 earnings per share estimates for MAIA Biotechnology in a note issued to investors on Thursday, November 14th. Diamond Equity analyst H. Diamond expects that the company will post earnings per share of ($0.25) for the quarter. The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($1.25) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.43) EPS and FY2025 earnings at ($1.35) EPS.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.21.

MAIA Biotechnology Trading Down 6.8 %

MAIA stock opened at $2.19 on Monday. The company has a market capitalization of $55.47 million, a P/E ratio of -1.59 and a beta of 0.32. MAIA Biotechnology has a 1-year low of $0.82 and a 1-year high of $5.99.

Hedge Funds Weigh In On MAIA Biotechnology

A number of hedge funds and other institutional investors have recently modified their holdings of MAIA. Geode Capital Management LLC raised its position in MAIA Biotechnology by 22.9% in the 3rd quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock worth $541,000 after purchasing an additional 35,821 shares during the period. XTX Topco Ltd purchased a new stake in MAIA Biotechnology during the third quarter valued at about $31,000. Ground Swell Capital LLC bought a new position in shares of MAIA Biotechnology during the second quarter valued at about $56,000. Mather Group LLC. grew its stake in shares of MAIA Biotechnology by 50,150.0% during the second quarter. Mather Group LLC. now owns 12,060 shares of the company’s stock valued at $41,000 after buying an additional 12,036 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of MAIA Biotechnology in the first quarter worth about $71,000. 5.65% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Cristian Luput purchased 22,133 shares of the stock in a transaction on Friday, November 1st. The shares were acquired at an average price of $2.51 per share, for a total transaction of $55,553.83. Following the completion of the transaction, the director now directly owns 389,483 shares of the company’s stock, valued at approximately $977,602.33. This trade represents a 6.03 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 36.98% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.